Sunday 18 October 2026 Export ACIU’s income statement to Excel — free account

AC Immune

AC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024. In the quarter to June 2026, revenue grew 29.7%, EPS grew 9.52% and free cash flow grew 4.66%, each against the same quarter a year earlier.

2.39 0.06 −2.45%

Follow ACIU

Alert me

Market cap: $249.4M
P/E: 0.0×
Fwd P/E: −5.3×
Dividend yield: —
F-score: 2/9
Altman Z: −3.99
Beneish M: 1.01
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.06

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	1	1	—	—	—	—	—

Insider Ownership 36.60%

Capital & Financial Ratios $m

Market Cap 249.35

Revenue 4.64

Net Income (80.22)

Free Cash Flow (83.67)

Net Debt (95.35)

Current Ratio 0.93

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.31)

P/S ratio 50.83

P/B ratio 5.30

Past 5Y EPS Growth —

This Y EPS Growth 39.33%

Next Y EPS Growth 147.39%

Next Y revenue growth 421.31%

Next 5Y EPS Growth 7.55%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 78.52%

10-year low 10-year high

P/B against its own 10 years 86.84%

10-year low 10-year high

EV/Sales against its own 10 years 79.64%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	115	188	110	95
Receivables	17	1	1	17
Inventory	—	—	—	—
Other	0	1	0	0
	139	195	117	118

	2023	2024	2025	Q'26
Payables	2	3	2	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	15	115	114	127

Compound Annual Growth %

	10y	5y	3y
Sales	—	(47.84%)	1.51%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(3.06%)	(25.10%)	(32.62%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	—	—	—	—
’25	1	2	1	0	4
’24	—	1	29	1	31
’23	—	—	—	—	16
’22	—	—	4	0	4
’20	13	1	1	1	16
’19	75	2	34	1	112

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(20)	—	—	—
’25	(21)	(21)	(24)	(18)	(84)
’24	1	81	(13)	6	75
’23	(18)	(16)	(16)	(17)	(67)
’22	(25)	(19)	(14)	(19)	(77)
’21	(19)	(17)	(16)	(20)	(72)
’20	(10)	(15)	(18)	(20)	(63)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(20)	—	—	—
’25	(21)	(21)	(24)	(18)	(85)
’24	1	81	(13)	5	74
’23	(18)	(16)	(16)	(17)	(68)
’22	(26)	(20)	(14)	(19)	(78)
’21	(20)	(18)	(16)	(21)	(75)
’20	(10)	(16)	(18)	(21)	(65)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.19)	—	—	—	—
’25	(0.21)	(0.25)	(0.20)	(0.18)	(0.84)
’24	(0.21)	(0.25)	0.06	(0.18)	(0.58)
’23	(0.23)	(0.22)	(0.20)	(0.06)	(0.71)
’22	(0.25)	(0.24)	(0.17)	(0.24)	(0.89)
’21	(0.25)	(0.29)	(0.24)	(0.28)	(1.06)
’20	(0.11)	(0.23)	(0.28)	(0.30)	(0.92)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	10.36	6.03	7.16	3.25	4.07	4.68	1.68	1.78	2.25	1.43	Analyst estimates 2026–2028 Powerpack
	High	19.97	14.06	17.40	12.15	13.00	12.61	5.21	5.14	5.04	4.00
People
People	Employees	67	86	104	132	149	143	156	161	172	122
	Revenue/emp, $m	0.35	0.24	0.07	0.85	0.11	0.00	0.03	0.10	0.18	0.04
Income, $m
Income, $m	Revenue	24	21	7	112	16	—	4	16	31	4
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	0.00	100.00	100.00	100.00	100.00
	EBT	(7)	(27)	(52)	46	(66)	(80)	(74)	(60)	(58)	(85)
	EBT margin, %	(30.57)	(130.39)	(708.25)	40.93	(401.28)	0.00	(1,797.71)	(366.35)	(186.43)	(1,971.65)
	Net income	(7)	(27)	(52)	46	(66)	(80)	(74)	(60)	(58)	(85)
	Depreciation	0	1	1	1	2	3	2	2	2	3
Per share, $
Per share, $	Revenue	0.47	0.36	0.12	1.58	0.23	0.00	0.05	0.19	0.31	0.04
	Earnings	(0.14)	(0.47)	(0.84)	0.64	(0.92)	(1.06)	(0.89)	(0.71)	(0.58)	(0.84)
	Cash flow	(0.11)	(0.39)	(0.73)	0.79	(0.88)	(0.96)	(0.92)	(0.79)	0.75	(0.83)
	Capex	(0.02)	(0.03)	(0.03)	(0.03)	(0.02)	(0.04)	(0.02)	(0.01)	(0.01)	(0.01)
	Free cash flow	(0.13)	(0.43)	(0.76)	0.76	(0.91)	(1.00)	(0.94)	(0.80)	0.74	(0.84)
	Book value	2.89	2.08	2.94	3.88	3.20	3.39	2.12	2.11	1.28	0.54
	Shares, m	50	57	62	71	72	75	84	85	100	101
Valuation, ×
Valuation, ×	P/E	37.17	0.00	0.00	12.72	0.00	—	0.00	0.00	0.00	0.00
	P/S	0.00	37.02	79.45	5.38	22.59	—	28.75	61.84	8.66	73.36
	P/B	4.30	6.42	3.22	2.19	1.62	—	1.04	2.22	2.11	5.84
	EV/Sales	0.00	30.90	53.60	2.81	8.09	—	9.13	44.36	2.69	48.34
	EV/FCF	12.52	(26.19)	(8.39)	5.84	(2.04)	—	(0.75)	(4.18)	1.13	(2.46)
Cash, $m
Cash, $m	Operating cash flow	(6)	(22)	(45)	56	(63)	(72)	(77)	(67)	75	(84)
	Capex	(1)	(2)	(2)	(2)	(2)	(3)	(1)	(1)	(1)	(1)
	Free cash flow	(7)	(24)	(47)	54	(65)	(75)	(78)	(68)	74	(85)
Balance, $m
Balance, $m	Working capital	147	122	184	277	232	200	122	124	81	2
	Total debt	—	0	1	1	3	3	3	—	—	—
	Net debt	(155)	(126)	(190)	(290)	(241)	(217)	(128)	(115)	(188)	(110)
	Shareholders’ equity	145	119	182	274	230	254	177	179	128	54
Returns, %
Returns, %	ROA	(5.96)	(18.34)	(31.09)	18.22	(23.76)	(29.54)	(30.84)	(30.32)	(24.83)	(37.92)
	ROIC	0.00	0.00	0.00	0.00	0.00	(146.26)	(95.42)	(58.19)	0.00	0.00
	ROE	(6.59)	(20.39)	(34.69)	20.07	(26.21)	(33.03)	(34.41)	(33.94)	(37.74)	(93.59)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)	Compare
RCKT Rocket Pharmaceuticals, Inc.	$259.1M	— (loss-making)	—	—	n/m	+19.16% (above 0%: growing)	0.00%	0.00%	Compare
VNDA Vanda Pharmaceuticals Inc.	$256.4M	— (loss-making)	— (loss-making)	−3.92% (below 0%: shrinking)	n/m	−101.02% (below 0%: shrinking)	92.95%	(126.28%)	Compare
IKT Inhibikase Therapeutics, Inc.	$255.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−123.23% (below 0%: shrinking)	0.00%	0.00%	Compare
LCTX Lineage Cell Therapeutics, Inc.	$250.5M	— (loss-making)	— (loss-making)	−61.34% (below 0%: shrinking)	n/m	−32.40% (below 0%: shrinking)	100.00%	(834.71%)	Compare
ACIU AC Immune	$249.4M	— (loss-making)	— (loss-making)	+29.66% (above 0%: growing)	n/m	+4.66% (above 0%: growing)	100.00%	(1,321.50%)
BBOT BridgeBio Oncology Therapeutics, Inc	$236.5M	— (loss-making)	—	—	n/m	−88.78% (below 0%: shrinking)	—	0.00%	Compare
SABS SAB Biotherapeutics, Inc.	$235.7M	— (loss-making)	19.9×	−90.95% (below 0%: shrinking)	n/m	−59.75% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$255.9M	—	—	−61.34%	—	−47.74%	81.64%	0.00%

All 614 Biotechnology stocks →

AC Immune (ACIU) key facts

Concern: AC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024.
AC Immune (ACIU) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ACIU traded at $2.39, a market capitalization of $249.4 million.
Return on equity was −93.6% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −3.99 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.